{"result": "(\"entity\"<|>PAMIDRONATO<|>EVENT<|>Pamidronate is an intravenous medication used to treat conditions associated with high calcium levels in the blood, such as hypercalcemia.)\n##\n(\"entity\"<|>FUROSEMIDA<|>EVENT<|>Furosemide is a diuretic medication used to treat fluid retention and high blood pressure, which can also be relevant in managing hypercalcemia.)\n##\n(\"entity\"<|>SUERO SALINO<|>EVENT<|>Saline solution is used in medical treatments, including hydration and electrolyte balance, and can be part of the management for hypercalcemia.)\n##\n(\"entity\"<|>CALCIO<|>EVENT<|>Calcium is a vital mineral in the body, and its levels are crucial in various physiological processes, including bone health and muscle function.)\n##\n(\"entity\"<|>VITAMINA D<|>EVENT<|>Vitamin D is a nutrient that helps the body absorb calcium and is important for maintaining bone health.)\n##\n(\"entity\"<|>HIPOCALEMIA<|>EVENT<|>Hypocalcemia is a medical condition characterized by low levels of calcium in the blood, which can lead to various health issues.)\n##\n(\"relationship\"<|>PAMIDRONATO<|>HYPERCALCEMIA<|>Pamidronate is used as a treatment for hypercalcemia, helping to lower elevated calcium levels in the blood<|>8)\n##\n(\"relationship\"<|>FUROSEMIDA<|>HYPERCALCEMIA<|>Furosemide can be used in the management of hypercalcemia by promoting diuresis and reducing fluid overload<|>6)\n##\n(\"relationship\"<|>SUERO SALINO<|>HYPERCALCEMIA<|>Saline solution can be administered to help manage hypercalcemia by maintaining hydration and electrolyte balance<|>5)\n##\n(\"relationship\"<|>CALCIO<|>HYPERCALCEMIA<|>High levels of calcium in the blood characterize hypercalcemia, making calcium a central focus in its diagnosis and treatment<|>9)\n##\n(\"relationship\"<|>VITAMINA D<|>HYPERCALCEMIA<|>Vitamin D plays a crucial role in calcium metabolism, and its levels can influence the occurrence of hypercalcemia<|>4)\n##\n(\"relationship\"<|>HIPOCALEMIA<|>HYPERCALCEMIA<|>Hypocalcemia is the opposite condition of hypercalcemia, and understanding both is essential in managing calcium-related disorders<|>3)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: de la hipercal-\n        dos radiotrazadores (escintigrafía de isótopos duales). El uso de tecnecio más un segundo                                                         cemia grave. Sin embargo, la calcitonina consigue pocas veces un descenso del calcio\n        radiotrazador como el pertecnetato (talio), 123I o 99mTc permite obtener imágenes selectivas                                                      sérico de más de 1 a 2 mg/dl y su eficacia dura pocos días como máximo, probablemente\n        de la glándula tiroides.                                                                                                                          por la disminución del número de receptores en las células de actuación en el hueso y en\n        Al igual que con las técnicas basadas en sestamibi, la sensibilidad del ultrasonido para la                                                       el riñón. Sus ventajas principales son un inicio de acción más rápido que los bisfosfona-\n        localización del adenoma paratiroideo se reduce en pacientes con nódulos tiroideos.                                                               tos y su capacidad para aumentar directamente la excreción renal de calcio.\n                                                                                                                                                          Referencias:\n        Referencias:                                                                                                                                      • Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016.\n        • Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016.                 • Shane E, Berenson JR. Treatment of hypercalcemia. Rosen CJ, ed. UptoDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com\n        • Yip L, Silverberg SJ, El-Hajj Fuleihan G. Preoperative localization for parathyroid surgery in patients with primary hyperparathyroi-             (acceso 6 de junio de 2019).\n          dism. Sally CE, Rosen CJ, eds. UptoDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso 6 de junio de 2019).\n\n\n\n     7  Un paciente de 68 años es ingresado con una masa pulmonar y una cifra de calcio                                                          7.2 Hipocalcemia\n        sérico de 15,7 mg/dl. ¿Cuál es la primera medida terapéutica que se ha de adoptar?\n        A. Pamidronato intravenoso.                                                                                                                 8     ¿Qué patología puede producir una hipocalcemia con PTH baja?\n        B. Furosemida.                                                                                                                                    A. Síndrome poliglandular autoinmune.\n        C. Suero salino.                                                                                                                                  B. Hipomagnesemia.\n        D.  Calcitonina.                                                                                                                                  C. Enfermedad de Wilson.\n                                                                                                                                                          D.  Todas son ciertas.\n\n\n\n378                                                                                                                                                                                                                                                                               379\n---\n                                                                                                                                                                 METABOLISMO FOSFOCÁLCICO,                                          TUMORES                          7\n                                                                                                                                                                                               NEUROENDOCRINOS Y MEN\n\n\n\n        COMENTARIO                                                                                                                             El aumento del consumo de calcio disminuye el hiperparatiroidismo secundario observado\n        La hipocalcemia asociada a disfunción paratiroidea se distingue de otras causas de hipocal-                                            a menudo al avanzar la edad y puede incrementar la mineralización del hueso recién for-\n        cemia porque la PTH es baja (hipoparatiroidismo) o inapropiadamente normal si se mantiene                                              mado. La ingesta óptima de calcio y vitamina D es incierta. En mujeres posmenopáusicas\n        cierto grado de producción de PTH. Por el contrario, la concentración de PTH es alta en los                                            con osteoporosis se recomiendan 1.200 mg de calcio/día (dieta más suplemento si                                     es\n        síndromes asociados a resistencia a los efectos biológicos de la PTH.                                                                  necesario) y 800 UI/día de vitamina D. Aunque varios ensayos han informado de un efecto\n                                                                                                                                               beneficioso del calcio o calcio más vitamina D sobre la densidad ósea en mujeres posme-\n        En el síndrome poliglandular autoinmune tipo 1 (poliendocrinopatía autoinmunitaria, can-                                               nopáusicas y hombres mayores, los datos sobre las tasas de fractura son más variables.\n        didiasis y distrofia ectodérmica) se produce una disfunción permanente de las glándulas                                                Sin embargo, un metaanálisis reciente demostró un aumento escaso, pero uniforme de la\n        paratiroides por destrucción debido a autoanticuerpos. Se caracteriza por la tríada clásica                                            DMO y una disminución de las fracturas no vertebrales con 1.200 mg de calcio y 800 UI\n        de candidiasis mucocutánea, hipoparatiroidismo autoinmunitario y enfermedad de Addi-                                                   de vitamina D. El beneficio de esta suplementación parece ser mayor entre las personas\n        son, que constituyen tres de los componentes más habituales en el trast\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>ORGANIZATION<|>A comprehensive textbook on endocrinology, authored by Melmed S, Polonsky KS, Reed Larsen P, and Kronenberg HM, published by Elsevier in its 13th edition in Philadelphia in 2016.)\n##\n(\"entity\"<|>UPTODATE<|>ORGANIZATION<|>A clinical decision support resource that provides evidence-based information for healthcare professionals, including treatment guidelines and medical updates, published by UpToDate Inc.)\n##\n(\"entity\"<|>SALLY CE<|>PERSON<|>An editor involved in the publication of medical literature, specifically in the context of UptoDate resources.)\n##\n(\"entity\"<|>E<|>PERSON<|>A person mentioned in the context of treatment of hypercalcemia, specifically in the reference to a publication by Rosen CJ.)\n##\n(\"entity\"<|>HYPERCALCEMIA<|>EVENT<|>A medical condition characterized by an abnormally high level of calcium in the blood, often requiring treatment.)\n##\n(\"entity\"<|>HYPOMAGNESEMIA<|>EVENT<|>A medical condition characterized by low levels of magnesium in the blood, which can lead to various health issues.)\n##\n(\"entity\"<|>SYNDROME POLIGLANDULAR AUTOINMUNE<|>EVENT<|>An autoimmune disorder characterized by the dysfunction of multiple endocrine glands, often leading to conditions like hypoparathyroidism.)\n##\n(\"entity\"<|>CALCITONINA<|>EVENT<|>A hormone produced by the thyroid gland that helps regulate calcium levels in the body, often used in treatment for conditions like hypercalcemia.)\n##\n(\"relationship\"<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>UPTODATE<|>Both are resources that provide medical information and guidelines for healthcare professionals, particularly in endocrinology<|>7)\n##\n(\"relationship\"<|>SALLY CE<|>UPTODATE<|>Sally CE is an editor associated with UptoDate, contributing to the medical literature published by the organization<|>6)\n##\n(\"relationship\"<|>E<|>UPTODATE<|>E is referenced in the context of treatment guidelines for hypercalcemia provided by UptoDate<|>5)\n##\n(\"relationship\"<|>HYPERCALCEMIA<|>CALCITONINA<|>Calcitonin is often used as a treatment for hypercalcemia, helping to lower calcium levels in the blood<|>8)\n##\n(\"relationship\"<|>HYPOMAGNESEMIA<|>SYNDROME POLIGLANDULAR AUTOINMUNE<|>Hypomagnesemia can be a condition associated with the autoimmune syndrome affecting parathyroid function<|>4)\n##\n(\"relationship\"<|>SYNDROME POLIGLANDULAR AUTOINMUNE<|>HYPERCALCEMIA<|>The autoimmune syndrome can lead to conditions that may result in hypercalcemia due to parathyroid dysfunction<|>3)\n<|COMPLETE|>"}]}